T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2021-09-08 , DOI: 10.1002/cti2.1341
Jose L Casado ₁ , Johannes Haemmerle ₂ , Pilar Vizcarra ₁ , Mario Rodriguez-Dominguez ₃ , Tamara Velasco ₁ , Hector Velasco ₄ , Elena Centenera ₁ , Beatriz Romero-Hernandez ₃ , Marina Fernandez-Escribano ₂ , Alejandro Vallejo _{1,

4}

Affiliation

Antibody response to the first dose of BNT162b2 SARS-CoV-2 is greater in COVID-19-convalescent than in infection-naïve individuals. However, there are no data about T-cell response in individuals with pre-existing cellular immunity.

中文翻译：